Roche Pharmaceutical Development and Sales Overview
2022/23: Upcoming Pharma newsflow
Vabysmo in RVO
2022
Susvimo in DME
Susvimo in DR
Venclexta in R/R MM (t11;14)
Gantenerumab in Alzheimer's disease
2023
Tiragolumab + Tecentriq in 1L PDL 1+ NSCLC
Tiragolumab + Tecentriq in 1L Esophageal
Tecentriq in adjuvant HCC
Tecentriq in adjuvant SCCHN
Tecentriq + chemo in adjuvant TNBC
Tecentriq neoadjuvant/adjuvant TNBC
Tecentriq periadjuvant NSCLC
Phesgo OBI in HER2+ BC
Alecensa in adjuvant ALK+ NSCLC
Venclexta in 1L high risk MDS
Crovalimab in PNH
Glofitamab in 2L+ DLBCL*
Lunsumio in 2L+ DLBCL*
Neuroscience
Oncology
Ophthalmology
Immunology
Delandistrogene moxeparvovec in DMD
Ocrevus SC in RMS / PPMS
TNKase in Stroke
Xolair in Food allergy
DME-diabetic macular edema; DLBCL-diffuse large B-cell lymphoma; NSCLC=non-small cell lung cancer; HCC-hepatocellular carcinoma; MM-multiple myeloma; RVO-retinal vein occlusion; CSF-cerebrospinal fluid;
PCR-polymerase chain reaction; SC=subcutaneous; *Results are event-driven, read-outs expected 2023/24
Roche
13View entire presentation